Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Jüppner H. Salusky IB, et al. Among authors: juppner h. J Am Soc Nephrol. 2005 Aug;16(8):2501-8. doi: 10.1681/ASN.2004100885. Epub 2005 Jun 8. J Am Soc Nephrol. 2005. PMID: 15944337 Clinical Trial.
The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).
Wesseling-Perry K, Harkins GC, Wang HJ, Elashoff R, Gales B, Horwitz MJ, Stewart AF, Jüppner H, Salusky IB. Wesseling-Perry K, et al. Among authors: juppner h. J Clin Endocrinol Metab. 2010 Jun;95(6):2772-80. doi: 10.1210/jc.2009-1909. Epub 2010 Apr 9. J Clin Endocrinol Metab. 2010. PMID: 20382692 Free PMC article.
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB. Wesseling-Perry K, et al. Among authors: juppner h. Kidney Int. 2011 Jan;79(1):112-9. doi: 10.1038/ki.2010.352. Epub 2010 Sep 22. Kidney Int. 2011. PMID: 20861820 Free article. Clinical Trial.
Early skeletal and biochemical alterations in pediatric chronic kidney disease.
Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, Jüppner H, Salusky IB. Wesseling-Perry K, et al. Among authors: juppner h. Clin J Am Soc Nephrol. 2012 Jan;7(1):146-52. doi: 10.2215/CJN.05940611. Epub 2011 Nov 3. Clin J Am Soc Nephrol. 2012. PMID: 22052943 Free PMC article.
Lack of FGF23 response to acute changes in serum calcium and PTH in humans.
Wesseling-Perry K, Wang H, Elashoff R, Gales B, Jüppner H, Salusky IB. Wesseling-Perry K, et al. Among authors: juppner h. J Clin Endocrinol Metab. 2014 Oct;99(10):E1951-6. doi: 10.1210/jc.2014-2125. Epub 2014 Jul 25. J Clin Endocrinol Metab. 2014. PMID: 25062462 Free PMC article. Clinical Trial.
Special aspects of renal osteodystrophy in children.
Salusky IB, Kuizon BG, Jüppner H. Salusky IB, et al. Among authors: juppner h. Semin Nephrol. 2004 Jan;24(1):69-77. doi: 10.1053/j.semnephrol.2003.08.009. Semin Nephrol. 2004. PMID: 14730512 Review.
338 results